Pulmonary Hypertension Secondary to Idiopathic Pulmonary Fibrosis And Treatment With Sildenafil
| Status: | Withdrawn |
|---|---|
| Conditions: | Lung Cancer, High Blood Pressure (Hypertension), Pulmonary |
| Therapuetic Areas: | Cardiology / Vascular Diseases, Oncology, Pulmonary / Respiratory Diseases |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 5/3/2018 |
| Start Date: | February 2007 |
| End Date: | December 2009 |
Randomized Placebo-Controlled Study of Sildenafil For The Treatment of Pulmonary Hypertension Secondary to Idiopathic Pulmonary Fibrosis: A Pilot Study
Pulmonary Arterial Hypertension (PAH) in the setting of Idiopathic Pulmonary Fibrosis(IPF)is
a risk factor for morbidity and mortality in the peri-lung transplant(LT) setting. Currently
there is no significant data to support the use of pulmonary vasodilators for PAH in the
setting of interstitial lung disease such as IPF. The majority of IPF patients have PAH
either at rest or during exercise. The study hypothesis is that sildenafil may improve
morbidity and mortality in the peri-LT setting in both IPF cohorts with either resting or
exercise PAH.
a risk factor for morbidity and mortality in the peri-lung transplant(LT) setting. Currently
there is no significant data to support the use of pulmonary vasodilators for PAH in the
setting of interstitial lung disease such as IPF. The majority of IPF patients have PAH
either at rest or during exercise. The study hypothesis is that sildenafil may improve
morbidity and mortality in the peri-LT setting in both IPF cohorts with either resting or
exercise PAH.
The purpose of this study is to evaluate the use of sildenafil in patients with pulmonary
fibrosis and PH being considered for lung transplantation. We hypothesize that not only will
sildenafil improve functionality and QOL in the pre-transplant setting but it may also
improve primary graft dysfunction after lung transplantation.
fibrosis and PH being considered for lung transplantation. We hypothesize that not only will
sildenafil improve functionality and QOL in the pre-transplant setting but it may also
improve primary graft dysfunction after lung transplantation.
Inclusion Criteria:
- Patients with Idiopathic Pulmonary Fibrosis referred for lung transplantation at our
medical center
- Minimal 6 minute walk distance of 50 meters; must be able to conduct supine exercise
during heart catheterization
Exclusion Criteria:
- Non ambulatory
- Prior adverse reaction/allergy to sildenafil or other PDE-5 Inhibitors
- Any other pulmonary vasodilator within one month of enrollment
We found this trial at
1
site
10833 Le Conte Ave
Los Angeles, California 90095
Los Angeles, California 90095
(310) 825-4321
David Geffen School of Medicine, UCLA In 2002 Mr. David Geffen announced a $200 million...
Click here to add this to my saved trials
